financetom
Business
financetom
/
Business
/
Carrier Global CEO Forecasts Up to 30% Growth in Q3 Orders
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Carrier Global CEO Forecasts Up to 30% Growth in Q3 Orders
Sep 11, 2024 12:00 PM

02:30 PM EDT, 09/11/2024 (MT Newswires) -- Carrier Global ( CARR ) is forecasting growth of up to 30% for its orders in Q3, Chief Executive Officer David Gitlin said.

Gitlin told participants at a Morgan Stanley conference that the company has "seen continued orders in the first couple of months of this quarter in [the] 20% to 30% range."

Gitlin also said the company had a "very focused portfolio" after reaching an agreement to divest five businesses in just over a year, according to a transcript available of the event on S&P Capital IQ.

Gitlin said Carrier's portfolio was now predominantly made up of heating, ventilation, and air conditioning, with the rest comprising of transport, refrigeration and coldchain.

The company continues to grow market share and margins in the commercial HVAC sector thanks to a "once-in-a-lifetime opportunity" with data centers, according to Gitlin.

"Residential light commercial in North America, we have very high margins, good market share, but there's a lot of moving parts in the system with the refrigerant change," Gitlin told participants.

Carrier Global's ( CARR ) Q2 net sales rose to $6.69 billion from $5.99 billion a year earlier but did not meet the Capital IQ estimate of $7.07 billion.

At the time, Carrier Global ( CARR ) also lowered its sales outlook for the year to $25.50 billion from $26 billion previously.

"We see a return to growth as we get into next year," Gitlin said.

Carrier Global ( CARR ) shares were up 2.7% in recent Wednesday trading.

Price: 73.75, Change: +1.92, Percent Change: +2.67

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sri Lanka gives preliminary approval to Musk's Starlink
Sri Lanka gives preliminary approval to Musk's Starlink
Jun 6, 2024
COLOMBO, June 6 (Reuters) - Sri Lanka has given preliminary approval to Elon Musk's Starlink, the satellite unit of SpaceX, to provide internet services in the country, the president's office said on Thursday. ...
OSI Systems Insider Sold Shares Worth $6,320,312, According to a Recent SEC Filing
OSI Systems Insider Sold Shares Worth $6,320,312, According to a Recent SEC Filing
Jun 6, 2024
03:07 AM EDT, 06/06/2024 (MT Newswires) -- Alan I Edrick, Executive Vice President and Chief Financial Officer, on June 03, 2024, sold 44,082 shares in OSI Systems ( OSIS ) for $6,320,312. Following the Form 4 filing with the SEC, Edrick has control over a total of 296,833 shares of the company, with 296,833 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1039065/000141588924015692/xslF345X03/form4-06052024_090602.xml...
No-tariff shipments popular with Shein, Temu hit US customs speedbump
No-tariff shipments popular with Shein, Temu hit US customs speedbump
Jun 6, 2024
LOS ANGELES (Reuters) -A new U.S. crackdown on customs brokers handling billions of dollars in inexpensive online shopping orders from giants like China-linked Shein and Temu is likely to cause delivery delays and bottlenecks, industry experts said. U.S. Customs and Border Protection announced late last week it suspended multiple brokers from an expedited clearance program for those duty-free, direct-to-consumer imports...
Novartis and others face Italy antitrust probe over eye drug
Novartis and others face Italy antitrust probe over eye drug
Jun 6, 2024
ROME, June 6 (Reuters) - Italy's antitrust regulator said on Thursday it had launched a probe into several pharmaceutical companies, including Novartis, for having potentially restricted competition in the sale of a drug for eye conditions. Samsung Bioepis, Biogen, Genentech and Novartis, and some of their Italian, Dutch and UK units, allegedly coordinated their commercial strategies to delay the launch...
Copyright 2023-2026 - www.financetom.com All Rights Reserved